A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2013
At a glance
- Drugs ABT 436 (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Therapeutic Use
- 07 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Aug 2015 as reported by ClinicalTrials.gov.
- 07 Oct 2013 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 04 Jun 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.